title: UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer.
abstract: Locally advanced or metastatic adenocarcinoma of the stomach still carries a poor prognosis, with 5-year survival rates of < 15%. Palliative chemotherapeutic regimens for this disease are largely 5-FU-based. We have investigated the clinical activity of an oral combination of uracil and tegafur (UFT) with calcium folinate (Orzel), in patients with measurable metastatic disease. Thirty-six patients received a total of 94 courses of daily UFT 300 mg/m2 plus calcium folinate 90 mg for 28 consecutive days followed by a 7-day rest. Planned treatment doses were maintained in 83% of all evaluable courses. Main toxicities included diarrhea (21 patients) and nausea and vomiting (20 patients). Other side effects were asthenia, malaise, stomatitis, and myelosuppression. At present, 26 patients are evaluable for response. Of these, one achieved a complete response and three achieved partial remissions. In addition, six patients reached stable disease, yielding an overall response rate of 27%. We conclude that the combination of UFT and calcium folinate is a feasible outpatient regimen that warrants further clinical evaluation.
authors.affiliation: Institut Bergonié Bordeaux, France.
authors.forename: A
authors.initials: A
authors.lastname: Ravaud
authors.forename: M
authors.initials: M
authors.lastname: Borner
authors.forename: J H
authors.initials: JH
authors.lastname: Schellens
authors.forename: L
authors.initials: L
authors.lastname: Geoffrois
authors.forename: P
authors.initials: P
authors.lastname: Schöffski
authors.forename: J
authors.initials: J
authors.lastname: Wanders
authors.forename: A R
authors.initials: AR
authors.lastname: Hanauske
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000556:secondary*; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005500:Follow-Up Studies; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D010166:Palliative Care; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology*; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D005641:Tegafur; D014498:Uracil; D002955:Leucovorin